About Larimar Therapeutics, Inc. - Common Stock (LRMR)
Larimar Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those affecting the connective tissue. The company's primary research efforts center on leveraging its expertise in biochemistry to create novel treatments aimed at addressing the underlying causes of conditions like fibrosis and other systemic disorders. By prioritizing patient-centric solutions and embracing advanced scientific approaches, Larimar Therapeutics seeks to improve the quality of life for individuals affected by these challenging health conditions while advancing the field of therapeutic development. Read More
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Larimar Therapeutics shares long-term OLE study data on nomlabofusp, showing increased FXN levels in Friedreich's Ataxia patients and well-tolerated treatment.
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans to submit for FDA approval in late 2025, addressing a critical patient demographic.
